A promising new HIV vaccine was set to start trials. Then came Trump's latest cuts

A vaccine pharmacist prepares samples as part of an HIV vaccine trial on March 16, 2022 in Masaka, Uganda. The vaccine in that trial did not prove effective. A promising vaccine development program funded by the National Institutes of Health was just informed by the Trump administration that its support will end next year.

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine development program will end next year.

(Image credit: Luke Dray)